National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Nivolumab (Opdivo®) as monotherapy for the adjuvant treatment of adults with melanoma  with involvement of lymph nodes or metastatic disease who have undergone complete resection.

NCPE Assessment Process Complete
Rapid review commissioned 09/07/2018
Rapid review completed 27/07/2018
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of nivolumab compared with the current standard of care.